Recursion Pharmaceuticals
AI-native drug discovery platform turning 50+ PB of cellular imaging data into clinical-stage therapies
Recursion is the strongest enterprise bet in AI drug discovery for pharma partners needing deep data and validated clinical progress. Recent wins—Genentech optioning the first neuroscience target and advancing REC-1245—show momentum. But the partnership-only model locks out smaller players, and value realization demands serious resource commitment. If you can play long-term, it's a contender; otherwise, look elsewhere.
Verified 10d ago · liveness 60/100 · cite: rightaichoice.com/tools/recursion-pharma
- Large pharma seeking AI-driven partnerships for oncology or rare disease pipelines
- Investors looking for a TechBio with validated platform and clinical-stage assets
- Computational biology teams needing high-quality multi-omics data for discovery
- Organizations with long development timelines and appetite for first-in-class therapies
- Early-stage startups needing low-cost, self-serve AI drug discovery tools
- Academic labs wanting open-source or freemium access to drug discovery AI
- Therapies outside Recursion's focus areas (oncology and rare diseases)
We scan live Reddit threads, YouTube comments, X posts, G2 reviews and other communities — and hand you an honest verdict in under a minute.
- Honest verdict, not marketing
- Real pros & cons from real users
- Attributed quotes with receipts
3 free scans · no card needed
Skip Recursion if you are an early-stage startup or academic lab needing affordable, self-serve AI drug discovery tools, or if you cannot commit to a deep, multi-year partnership with significant resource investment.
The platform is only accessible through custom enterprise partnerships, meaning there is no fixed price—engagement costs can run into millions of dollars and require substantial internal scientific and technical
Recursion's pricing is not public and is structured as custom partnerships—this fits large pharma and well-funded biotechs ready to invest heavily in AI-driven discovery. If you need a lower-cost, self-serve option, Insilico Medicine or Atomwise may offer more accessible entry points, though with less comprehensive data integration.
In short
Recursion Pharmaceuticals — AI-native drug discovery platform turning 50+ PB of cellular imaging data into clinical-stage therapies. Best for Large pharma seeking AI-driven partnerships for oncology or rare disease pipelines, Investors looking for a TechBio with validated platform and clinical-stage assets, Computational biology teams needing high-quality multi-omics data for discovery. Contact Sales pricing.
What's new in Recursion Pharmaceuticals
Checked 10 days agoAcross the latest 3 updates: 3 news mentions.
Recursion Reports Q2 2026 Financial Results; Genentech Options First Neuroscience Target
Genentech advances first neuroscience target into joint early discovery program, validating Recursion's platform for target discovery. REC-4881 Phase 2 data update.
Recursion to Report Second Quarter 2026 Business Updates and Financial Results on August 5th
Recursion will host public earnings call on Aug 5, 2026 at 8:00 am ET to discuss Q2 2026 business updates and financial results.
Recursion Reports Q1 2026 Financial Results and Business Update
REC-1245 (RBM39 degrader) shows well-tolerated safety and predictable PK in solid tumors; no DLTs observed, supporting dose escalation.
Viability Score
How well maintained and how widely used is Recursion Pharmaceuticals? Built from what the vendor actually publishes (docs, changelog, tutorials, integrations, pricing), whether the site is live, and how much real users discuss it. How we calculate this
Last calculated: September 2026
How we score →Key Features
- AI-driven target identification via cellular imaging
- Recursion OS integrates phenomics, transcriptomics, proteomics
- Automated wet lab with robotics and computer vision (millions of cell experiments per week)
- Machine learning models for molecule design and optimization
- BioHive-2 supercomputer co-developed with NVIDIA
- Over 50PB proprietary biological and chemical dataset
- De-identified patient data integration for AI insights
- Generative AI for pharma drug discovery
- Phase 1/2 pipeline: REC-3565, REC-4881, REC-1245
- End-to-end from hit identification to IND-enabling studies
- Focus on oncology (solid tumors, lymphomas) and rare diseases
- Continuous feedback loop from wet lab to platform
- Partnership model for pharma collaborations (e.g., Genentech)
- Clinical-stage validation with first-in-class/best-in-class potential
About Recursion Pharmaceuticals
Recursion Pharmaceuticals is a clinical-stage TechBio company applying artificial intelligence to drug discovery, aiming to cut the 90% failure rate of traditional R&D. Its platform, the Recursion Operating System (Recursion OS), combines over 50 petabytes of proprietary biological and chemical data—spanning phenomics, transcriptomics, proteomics, ADME, and de-identified patient data—with machine learning models and an automated wet lab. The lab runs millions of cell experiments weekly using robotics and computer vision, feeding results back into the platform to create a continuous improvement loop. This end-to-end system accelerates everything from target identification to IND-enabling studies, and the company reports meaningful gains in speed, efficiency, and cost versus pharma averages. Recursion's pipeline targets high-unmet-need oncology and rare diseases. Recent progress includes REC-3565, a selective MALT1 inhibitor now in Phase 1 for relapsed/refractory B-cell lymphomas, and REC-1245, an RBM39 degrader showing a well-tolerated safety profile with dose-dependent PK in early solid tumor data. In August 2026, Genentech optioned the first neuroscience target from their collaboration, advancing it into joint early discovery. The company also partners with NVIDIA, co-developing BioHive-2, which they describe as biopharma's most powerful supercomputer, providing the compute muscle for their data-heavy approach. Compared to other AI drug discovery platforms like Insilico Medicine or Atomwise, Recursion offers a more comprehensive, data-driven approach grounded in cellular imaging and clinical-stage validation. However, access is primarily through enterprise partnerships, making it less accessible for early-stage startups or academic labs seeking low-cost or self-serve options. Recursion's value proposition is for organizations ready to commit to deep, long-term collaborations to fully leverage the platform's capabilities.
Behind the Verdict
Recursion stands out in the AI drug discovery landscape by combining an enormous proprietary dataset (50+ petabytes) with a fully automated wet lab that runs up to 2 million experiments weekly. This lab-in-the-loop design creates a continuous feedback loop: cell images and multi-omics data train ML models, which design molecules, which are tested back in the lab, and the results then refine the models. This is not a thin wrapper over a third-party LLM; it's a deep, vertically integrated R&D engine with proprietary data, robotics, and computational infrastructure (including BioHive-2, developed with NVIDIA). The clinical pipeline is advancing: REC-3565 (a MALT1 inhibitor) is in Phase 1 for B-cell lymphomas, REC-1245 (an RBM39 degrader) has shown a well-tolerated profile in solid tumors, and REC-4881 is moving through Phase 2. The August 2026 Genentech milestone—optioning the first neuroscience target—validates the platform's target discovery capabilities. For a large pharma or a biotech with deep pockets, Recursion offers a genuine end-to-end discovery capability that could meaningfully cut timelines and costs. However, access is gated behind enterprise partnerships with no public pricing, which locks out early-stage startups and academic labs. The cost and complexity of such collaborations are significant, and the value realization window is measured in years, not quarters. Recursion is not a fit for anyone needing a quick, low-cost, self-serve AI tool. But for organizations ready to commit to a long-term, data-driven discovery partnership, Recursion is arguably the most credible TechBio player today, with real clinical progress to back its claims.
Researching Recursion Pharmaceuticals? Get your full AI stack in 60 seconds.
Free, no signup — tell us your goal and get tools matched to your budget & existing stack.
Real-world workflow fit
Concrete scenarios for the personas Recursion Pharmaceuticals actually fits — and what changes day-one when you adopt it.
You are looking to expand your oncology pipeline with AI-discovered targets. You enter into a multi-year partnership with Recursion, gaining access to their lab-in-the-loop platform. Within the first year, you jointly validate a novel target from their imaging data and advance it into a preclinical program.
Outcome: You gain a de-risked, data-backed target that accelerates your pipeline, with Recursion's platform potentially cutting years off traditional discovery timelines.
You are evaluating Recursion as a TechBio investment. You review their Q2 2026 financials and see that Genentech has optioned a neuroscience target, validating their platform. You analyze their cash runway and pipeline progress (REC-3565, REC-1245, REC-4881) to assess clinical catalysts.
Outcome: You gain confidence in Recursion's business model and clinical execution, helping you decide to invest based on tangible milestones and partnership momentum.
Your team is considering a collaboration with Recursion to access their multi-omics dataset and AI tools for target discovery. You engage in a pilot project where your team provides a list of disease indications and Recursion runs 2 million cell experiments a week to identify candidate targets.
Outcome: You receive a shortlist of AI-prioritized targets with supporting imaging and omics evidence, significantly reducing your target identification workload and giving you a data-rich starting point.
Use Cases
- Identifying novel drug targets for oncology using cellular imaging
- Accelerating hit-to-lead for rare diseases with multi-omics data
- Optimizing lead compounds using machine learning models
- Designing molecules for first-in-class treatments
Models Under the Hood
as of 2026-08-31
Limitations
- Recursion's platform is enterprise-only, offered through partnerships, with no public pricing or self-service access.
- The custom, high-cost nature of partnerships may exclude smaller organizations.
- It is focused on drug discovery and early-stage development, not on clinical-stage execution.
as of 2026-08-28
Verification history
We have re-verified Recursion Pharmaceuticals 18 times since . Each pass re-reads the vendor's own pages and re-checks every listed field against that evidence; passes where nothing had changed are marked as such.
- — re-verified summary, description, our verdict, our analysis, pricing model, pricing tiers, features, integrations, who it suits, who should skip it
- — re-verified summary, description, our verdict, our analysis, pricing model, pricing tiers, features, integrations, who it suits, who should skip it
- — re-verified summary, description, our verdict, our analysis, pricing model, pricing tiers, features, integrations, who it suits, who should skip it
- — re-verified summary, description, our verdict, our analysis, pricing model, pricing tiers, features, integrations, who it suits, who should skip it
- — re-verified summary, description, our verdict, our analysis, pricing model, pricing tiers, features, integrations, who it suits, who should skip it
- — re-verified summary, description, our verdict, our analysis, pricing model, pricing tiers, features, integrations, who it suits, who should skip it
Showing the 6 most recent of 18 verification passes.
Free to cite with attribution — this page re-verifies continuously.
Where the pricing makes sense
The company stage and team size where Recursion Pharmaceuticals's pricing actually pencils out — and where peers do it cheaper.
Recursion's pricing is not public and is structured as custom partnerships—this fits large pharma and well-funded biotechs ready to invest heavily in AI-driven discovery. If you need a lower-cost, self-serve option, Insilico Medicine or Atomwise may offer more accessible entry points, though with less comprehensive data integration.
Setup time & first value
How long it actually takes to get something useful out of Recursion Pharmaceuticals — broken out by persona, not the marketing-page minute.
For large pharma partners, initial onboarding—legal, data access, and platform integration—typically takes 1-3 months. Computational teams can then start seeing target hypotheses within weeks to a few months, given the automated lab's throughput. A full partnership's value realization is measured in years.
Switching to or from Recursion Pharmaceuticals
How to bring data in from common predecessors and how to get it back out — written for the switcher, not the buyer.
- →From traditional in-house drug discovery: Recursion's partnership model can augment your internal R&D with AI-driven target identification and lab automation. You would typically sign a collaboration agreement and
- ↗To Insilico Medicine: If you find Recursion's partnership commitment too heavy, Insilico offers AI-driven discovery with more flexible, potentially smaller-scale engagements.
Integrations
Resources & Guides
Tutorials & Learning
Official links
Tools that pair well with Recursion Pharmaceuticals
Common stack mates teams adopt alongside Recursion Pharmaceuticals, with the specific reason each pairing earns its keep.
Recursion
AI-native drug discovery: phenomics, robotics, and a 50+ petabyte dataset to de-risk medicines.
Insilico Medicine
End-to-end generative AI drug discovery platform from target ID to clinical trials, validated by a Phase III pipeline.
Insitro
Causal AI for human health, turning 20+ petabytes of cellular data into targeted therapeutics.
Alternatives to Recursion Pharmaceuticals
View all
Recursion
AI-native drug discovery: phenomics, robotics, and a 50+ petabyte dataset to de-risk medicines.
Insilico Medicine
End-to-end generative AI drug discovery platform from target ID to clinical trials, validated by a Phase III pipeline.
Frequently Asked Questions
Categories
Best-of guides
Used Recursion Pharmaceuticals? Help shape our editorial sentiment research.